Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2020-05-15 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed investor presentation dated 15th May, 2020
Regulatory Filings
2020-05-15 English
Outcome attached.
Regulatory Filings
2020-05-15 English
Letter dated 15th May 2020 is attached.
Regulatory Filings
2020-05-15 English
Letter dated 15th May 2020 is attached.
Regulatory Filings
2020-05-15 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a communication from Cipla Limited dated 15th May 2020, addressed to stock exchanges and regulatory bodies. It announces the outcome of a Board of Directors meeting held on the same day. The key points include approval of audited financial results (standalone and consolidated) for the quarter and year ended 31st March 2020, the auditors' report on these results, and a declaration from the CFO. Additionally, it discusses a fund raising plan subject to shareholder approval at the upcoming AGM. The document contains actual financial data tables and detailed financial results, not just an announcement or summary. This indicates it is a comprehensive financial report for the fiscal year ending 31 March 2020. The presence of audited financial results and auditors' report aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K).
2020-05-15 English
Financial Result Updates
Regulatory Filings
2020-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.